SARS-CoV-2 vaccination, Parkinson's disease, and other movement disorders: case series and short literature review.

Publisher: Springer-Verlag Italia Country of Publication: Italy NLM ID: 100959175 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1590-3478 (Electronic) Linking ISSN: 15901874 NLM ISO Abbreviation: Neurol Sci Subsets: MEDLINE

Original Publication: Milano, Italy : Springer-Verlag Italia, c2000-

COVID-19*/prevention & control ; COVID-19 Vaccines*/adverse effects ; Movement Disorders*/etiology ; Movement Disorders*/therapy ; Parkinson Disease*/etiology ; Parkinson Disease*/therapy ; Vaccination*/adverse effects; Carbidopa/therapeutic use ; Deep Brain Stimulation ; Drug Combinations ; Humans ; Immunization, Secondary/adverse effects ; Levodopa/therapeutic use ; Male ; Middle Aged ; Treatment Outcome

Background: Several neurological complications have been reported following SARS-Cov-2 vaccination, without a clear causal relationship ever being verified, including some cases of worsening of Parkinson's disease (PD) symptoms and new onset of movement disorders in non-parkinsonian patients.
Methods: We describe two new cases of PD patients treated with device-aided therapy who developed worsening of parkinsonian symptoms after receiving the third vaccine dose (booster). We also conducted a short review of the cases reported in literature of PD symptoms worsening and new onset of movement disorders in non-parkinsonian patients after SARS-Cov-2 vaccination.
Results: The first patient, a 46-year-old man implanted with bilateral Subthalamic Deep Brain Stimulation, experienced temporary motor and non-motor symptoms worsening after mRNA-1273 booster, improved after stimulation settings modification. The second patient, a 55-year-old man implanted with percutaneous endoscopic transgastric jejunostomy (PEG-J) for levodopa-carbidopa intestinal gel (LCIG) infusion experienced severe temporary worsening of dyskinesia and managed through temporary LCIG dose reduction. Other seven cases of vaccine-related movement disorder are currently reported in literature, four describing PD symptoms worsening and three the onset of new movement disorders in otherwise healthy people.
Conclusion: Both our patients and the cases described so far completely recovered after few days with parkinsonian therapy modification, symptomatic treatment, or even spontaneously, underlining the transient and benign nature of side effects from vaccine. Patients should be reassured about these complications, manageable through a prompt evaluation by the reference neurologist.
(© 2022. Fondazione Società Italiana di Neurologia.)

Garg RK, Paliwal VK (2022) Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci 43:3–40. https://doi.org/10.1007/s10072-021-05662-9. (PMID: 10.1007/s10072-021-05662-934719776)
Bloem BR, Trenkwalder C, Sanchez-Ferro A, Kalia LV, Alcalay R, Chiang HL, Kang UJ, Goetz C, Brundin P, Papa SM (2021) COVID-19 vaccination for persons with Parkinson’s disease: light at the end of the tunnel? J Parkinsons Dis 11:3–8. https://doi.org/10.3233/JPD-212573. (PMID: 10.3233/JPD-212573335230217990445)
Antonini A, Leta V, Teo J, Chaudhuri KR (2020) Outcome of Parkinson’s disease patients affected by COVID-19. Mov Disord 35:905–908. https://doi.org/10.1002/mds.28104. (PMID: 10.1002/mds.28104323475727267273)
Schneider SA, Hennig A, Martino D (2021) Relationship between COVID-19 and movement disorders: a narrative review. Eur J Neurol 29:1243–1253. https://doi.org/10.1111/ene.15217. (PMID: 10.1111/ene.1521734918437)
Erro R, Buonomo AR, Barone P, Pellecchia MT (2021) Severe dyskinesia after administration of SARS-CoV2 mRNA vaccine in Parkinson’s disease. Mov Disord 36:2219. https://doi.org/10.1002/mds.28772. (PMID: 10.1002/mds.28772343689918441657)
Cosentino C, Torres L, Vélez M, Nuñez Y, Sánchez D, Armas C, Alvarado M (2022) SARS-CoV-2 vaccines and motor symptoms in Parkinson’s disease. Mov Disord 37:233. https://doi.org/10.1002/mds.28851. (PMID: 10.1002/mds.2885134775612)
Matar E, Manser D, Spies JM, Worthington JM, Parratt KL (2021) Acute hemichorea-hemiballismus following COVID-19 (AZD1222) vaccination. Mov Disord 36:2714–2715. https://doi.org/10.1002/mds.28796. (PMID: 10.1002/mds.28796345814538661968)
Ryu DW, Lim EY, Cho AH (2022) A case of hemichorea following administration of the Pfizer-BioNTech COVID-19 vaccine. Neurol Sci 43:771–773. https://doi.org/10.1007/s10072-021-05763-5. (PMID: 10.1007/s10072-021-05763-534811599)
Shi Y, Guo M, Yang W, Liu S, Zhu B, Yang L, Yang C, Liu C (2021) Is SARS-CoV-2 vaccination safe and effective for elderly individuals with neurodegenerative diseases? Expert Rev Vaccines 20:375–383. https://doi.org/10.1080/14760584.2021.1911653. (PMID: 10.1080/14760584.2021.191165333787439)
Wang Q, Liu Y, Zhou J (2015) Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl Neurodegener 4:19. https://doi.org/10.1186/s40035-015-0042-0. (PMID: 10.1186/s40035-015-0042-0264647974603346)
Brugger F, Erro R, Balint B et al (2015) Why is there motor deterioration in Parkinson’s disease during systemic infections-a hypothetical view. NPJ Parkinsons Dis 1:15014. https://doi.org/10.1038/npjparkd.2015.14. (PMID: 10.1038/npjparkd.2015.14287256835516617)
Munro APS, Janani L, Cornelius V,: COV-BOOST study group, et al (2021) Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 398:2258–2276. https://doi.org/10.1016/S0140-6736(21)02717-3. (PMID: 10.1016/S0140-6736(21)02717-3348633588639161)

Keywords: Booster vaccination; COVID-19 vaccine; Movement disorders; Parkinson’s disease

0 (COVID-19 Vaccines)
0 (Drug Combinations)
46627O600J (Levodopa)
MNX7R8C5VO (Carbidopa)

Date Created: 20220606 Date Completed: 20220819 Latest Revision: 20220826

20231215

PMC9167915

10.1007/s10072-022-06182-w

35666352